trans- N- (1- (2- fluorophenyl)- 1h- pyrazol- 3- yl)- 1'- oxo- spiro(cyclohexane- 1,3'(1'H)- furo(3,4- C)pyridine)- 4- carboxamide

Also Known As:

spiro(cyclohexane-1,3'(1'H)-furo(3,4-C)pyridine)-4-carboxamide, N-(1-(2-fluorophenyl)-1h-pyrazol-3-yl)-1'-oxo-, trans-; MK-0557; MK0557; trans-N-(1-(2-fluorophenyl)-3-pyrazolyl)-3-oxospiro(6-azaisobenzofuran-1(3H),1'-cyclohexane)-4'-carboxamide

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Amatruda, John M: 3 articles (08/2007 - 10/2006)
2.	Erondu, Ngozi: 3 articles (08/2007 - 10/2006)
3.	Gantz, Ira: 3 articles (08/2007 - 10/2006)
4.	Heymsfield, Steven B: 3 articles (08/2007 - 10/2006)
5.	Kaufman, Keith D: 3 articles (08/2007 - 10/2006)
6.	Musser, Bret: 3 articles (08/2007 - 10/2006)
7.	Addy, Carol: 2 articles (08/2007 - 10/2006)
8.	Gottesdiener, Keith M: 2 articles (08/2007 - 10/2006)
9.	Mallick, Madhuja: 2 articles (08/2007 - 10/2006)
10.	Bays, Harold: 2 articles (04/2007 - 10/2006)

Related Diseases

1.	Weight Loss (Weight Reduction) 01/01/2007 - "One Y5 antagonist, MK-0557 was evaluated in a 1-yr clinical trial and found to cause modest weight loss. " 10/01/2006 - "We tested the hypothesis that blockade of the NPY5R will lead to weight loss in humans using MK-0557, a potent, highly selective, orally active NPY5R antagonist. " 04/01/2007 - "Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss." 04/01/2007 - "To evaluate whether MK-0557, a highly selective, orally administered neuropeptide Y Y5 receptor antagonist, could limit weight regain after very-low-calorie diet (VLCD)-induced weight loss. " 08/01/2007 - "Blockade of the NPY5R with the potent antagonist MK-0557 did not significantly increase the weight loss efficacy of either orlistat or sibutramine monotherapy."
2.	Body Weight (Weight, Body) 04/01/2007 - "Patients who lost>or=6% of initial body weight (n=359) were randomized to 52 weeks of 1 mg/d MK-0557 or placebo and maintained on a hypocaloric diet (300 kcal below weight maintenance requirements). "

Related Drugs and Biologics

1.	Orlistat (Xenical)
2.	sibutramine (Meridia)
3.	neuropeptide Y5 receptor
4.	Neuropeptide Y

Related Therapies and Procedures

1.	Caloric Restriction